Mabylon secures Eurostars grant worth 1.46 million euros Schlieren; to advance antibody therapy into clinical development

Mabylon secures Eurostars grant worth 1.46 million euros

30.04.2026, 12:17 UhrSchlieren - Mabylon has received 1.46 million euros from the Eurostars funding program for innovative SMEs. The financing will go toward the international ASCEND project, through which Mabylon aims to advance its antibody therapy for chronic intestinal diseases into clinical development.

(CONNECT)Mabylonhasannouncedthat it has received a grant of 1.46 million euros. The funding comes from theEurostarsprogram of the international innovation networkEUREKA, in which Switzerland and the European Union also participate. EUREKA is the world’s largest public network for international cooperation in research, development, and innovation, connecting stakeholders from industry and research to promote cross-border projects.

The grant will support the ASCEND project led by Mabylon. The project consortium, which includes the SwedishKarolinska Institutetand the French biotech companyAmbiotis, aims to advance the antibody therapy known as MY012 into clinical development for the treatment of chronic inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis.

MY012 is a monoclonal antibody that targets the inflammasome – a key driver of chronic inflammation – through a genetically validated mechanism by blocking the release of extracellular ASC protein. The consortium is reportedly combining human and animal disease models with biomarker development in order to position MY012 for clinical development as a highly differentiated therapy.

The biotech company Mabylon specializes in the development of human antibody therapies for allergies as well as neurological and inflammatory diseases. A key focus of its research is the modulation of inflammasomes, which are protein complexes of the innate immune system responsible for triggering inflammatory responses. Mabylon was founded in 2011 as a spin-off from theUniversity of Zurichand is headquartered at theBio-Technopark Schlieren-Zurich. ce

Chipeno pairs truffles with chipotle chilies in new sauce

Patent Medical presents Symbionic Teeth in Vienna

SIG Group expands in Mexico

FREITAG launches multifunctional Easy Riders bags

BTRY wins Hermes Startup Award 2026

Transferring home ownership within the family remains popular, says Raiffeisen

Bug Bounty Switzerland secures 12 million Swiss francs

Sirin Orbital Systems to research with ESA and the University of Málaga

Wir sind auch auf folgenden Social Media-Plattformen präsent. Bitte folgen Sie uns auch dort.